Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KROS
#4978
Keros Therapeutics, Inc. - common stock
0.1
1
USD
-99.01%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-99.01%
Monthly Change
-98.98%
6 month change
-99.35%
Year Change
-99.25%
Previous Close
11.3
9
Open
0.1
1
Low
0.1
1
High
0.1
1
Volume
43
Markets
US Stock Market
Healthcare
KROS
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
23.27 M
24 M
28.54 M
35.98 M
40.56 M
19.72 M
19.79 M
Valuation ratios
Enterprise value
1.38 B
1.17 B
1.03 B
1.22 B
82.17 M
114.03 M
-60.03 M
Price to earnings ratio
—
-23.22
-11.08
-8.29
-3.17
8.85
-4.42
Price to sales ratio
—
67.92
—
8 410.96
166.94
3.16
13.87
Price to cash flow ratio
—
21.97
16.56
10.2
3.68
7.17
-7.22
Price to book ratio
—
5.61
4.18
3.82
1.04
2.54
0.2
Enterprise value to EBITDA ratio
-29.66
-20.97
-9.05
-7.22
-0.39
1.66
0.55
Profitability ratios
Return on assets %
-0.17
-0.23
-0.34
-0.41
-0.3
0.26
-0.08
Return on equity %
-0.17
-0.24
-0.38
-0.46
-0.33
0.29
-0.08
Return on invested capital %
-8 687.99
-2 658.1
-2 572.76
-3 007.41
-3 105.79
785.01
-365
Gross margin %
—
100
—
100
100
100
100
Operating margin %
—
-280.46
—
-112.54 K
-5 938.96
27.71
-80.87 K
EBITDA margin %
—
-278.58
—
-112 K
-5 904.34
28.25
-80.65 K
Net margin %
—
-292.26
—
-101.32 K
-5 277.55
35.68
-74.09 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
37.27
21.23
17.27
14.25
21.45
15.45
22.62
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.08
0
0
0.01
0.72
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-2.66
-2.78
-4.23
-4.3
2.84
-1.55
EBIT per share
—
-2.42
-4.55
-5.77
-5.63
1.78
-3.47
EBITDA per share
—
-2.4
-4.52
-5.74
-5.6
1.82
-3.42
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9.86
11.06
11.25
14.96
7.59
14.34
Net current asset value per share
—
10.78
11.32
11.79
15.73
8.33
14.81
Tangible book value per share
—
10.42
10.99
11.28
15.27
8.01
14.55
Working capital per share
—
10.27
10.67
10.97
15
7.79
14.15
Book value per share
—
10.42
10.99
11.28
15.27
8.01
14.55
News
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?